Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
Bohula EA, Scirica BM, Inzucchi SE, et al.
The Lancet. Pub. online October 4, 2018
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Twice the benefits with twincretins?
Stumvoll M, Tschöp M
The Lancet. Pub. online October 4, 2018
Leggi
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Frias JP, Nauck MA, Van J, et al.
The Lancet. Pub. online October 4, 2018
Leggi
Enlarging the loop: closed-loop insulin delivery for type 1 diabetes
Galderisi A, Sherr JL
The Lancet. Pub. online October 3, 2018
Leggi
Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial
Tauschmann M, Thabit H, Bally L, et al.
The Lancet. Pub. online October 3, 2018
Leggi
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Hernandez AF, Green JB, Janmohamed S, et al.
The Lancet. Pub. online October 2, 2018
Leggi
Glucose lowering and the kidney: are all drug classes equal?
Wong MG, Jardine M, Perkovic V
Lancet Diabetes Endocrinol. Pub. online October 3, 2018
Leggi
Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
Muskiet MHA, Tonneijck L, Huang Y, et al.
Lancet Diabetes Endocrinol. Pub. online October 3, 2018
Leggi
Comparison of Medical Care Utilization and Costs Among Patients with Statin-Controlled Low-Density Lipoprotein Cholesterol With Versus Without Hypertriglyceridemia
Nichols GA, Philip S, Reynolds K, et al.
Am J Cardiol 2018; 122(7):1128-32
Leggi
Comparison of Frequency of Atherosclerotic Cardiovascular and Safety Events with Systolic Blood Pressure <120 mm Hg Versus 135-139 mm Hg in a Systolic Blood Pressure Intervention Trial Primary Prevention Subgroup
Plante TB, Juraschek SP, Miller III ER, et al.
Am J Cardiol 2018; 122(7):1185-90
Leggi